Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202).

Ahmed Sawas, MD[1], Hager Elgedawe[1], George Vlad, PhD[1], Mikel Lipschitz[2], Pei-Hsuan Chen[2], Scott J.Rodig, MD, Ph[3], Jennifer Lue, MD[1], Changchun Deng, MD, PhD[1], Jennifer E Amengual, MD[1], Maher Abdul-Hay, MD[4], Karen Khan, RN[1], Laine Atkins, RN[1], Aishling Rada, RN[1],Larisa Geskin, MD[1] and Owen A. O'Connor, MD, PhD[1]

[1]Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, [2]Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA. [3]Brigham & Women's Hospital, Boston, Massachusetts; Boston, MA.[4] New York University Perlmutter Cancer Center, New York, NY.

BACKGROUND

- AFM13 is a CD30/CD16A targeting high affinity bispecific tetravalent antibody that engages and activates NK cells.



METHODS

- Population : subjects with relapsed or refractory CD30 expressing lymphoma with cutaneous involvement

Cohort	Dose regimen			Total exposure
	Dose	Schedule	Duration	
Cohort 1	1.5 mg/kg	weekly	weeks 1-8	12 mg/Kg
Cohort 2	7.0 mg/kg	weekly	weeks 1-8	56 mg/Kg
Cohort 3	7.0 mg/kg CIVI *	weekly	weeks 1-8	56 mg/Kg

*1 mg/kg loading 6mg/kg as continuous infusion for 5 days per week

- Response assessment performed by mSWAT, photography, PET imaging and peripheral blood flow cytometry.
- A second cycle was administered if there was no progression of disease.
- Skin biopsies, whole blood and plasma were collected: pretreatment, day 5 post first dose, week 4 and week 8 of therapy.
- Tumor biopsies were analyzed and evaluated by a pathologist and IHC image analyzer to characterize immune cell subpopulations.
- Peripheral blood samples were analyzed by flow cytometry.

RESULTS

Patient Demographics Table	N= 9
Median Age, (range)	65 (37-79)
Male (%)	6 (67%)
Race (% white/ non-white)	33%/67%
Median number prior therapy, (range)	4 (1-11)
Patients progressed on Brentuximab vedotin	2
Total Skin Electron Beam Radiotherapy	5
Disease Histologies	
Transformed Mycosis Fungoides (T-MF)	4
Mycosis Fungoides, non-transformed (MF)	2
Systemic Anaplastic Large Cell Lymphoma-ALK negative (S- ALCL, ALK -)	2
Cutaneous Anaplastic Large Cell Lymphoma (C-ALCL)	1

Cohort	Disease	Toxicity	Response
1	S-ALCL, Alk (-)	No AE	PR
	T-MF	No AE	POD
	C- ALCL	Rash (G4) Skin infection (G3)	CR
2	MF	IRR (G1)	SD
	T-MF	IRR (G1)	SD
	T-MF	Skin infection (G3) IRR (G1)	Not assessed
3	T-MF	No AE	PR
	S-ALCL, Alk (-)	No AE	PR
	MF	No AE	POD

Rapid and Durable Response in TMF

Response in a TMF subject then consolidated with an Allogenic stem cell transplant. Responses were seen in:

- Nodes
- Skin,
- Peripheral blood



Skin Response in TMF Patient



Biomarker Correlatives



- Decrease in circulating NK cells during therapy with post therapy recovery, by following cells CD56+ CD3- , CD56+ CD16+ and NKp46+.
- Increase CD69 expression on circulating NK cells from responders vs. non-responders.
- Tumor biopsies showed increased infiltration of CD56+ NK cells pre therapy in responders vs. non-responders.
- Circulating CD4+ CD25+ T cells (Tregs) decrease in responders vs. non-responders.

CONCLUSION

- AFM13 demonstrated a high ORR of 44 %
- AFM13 is active post Brentuximab vedotin failure.
- Possible correlation between response and tumor NK cell infiltration pre therapy.

Abstract No. 2908
American Society of Hematology, December 2018, San Diego, CA.

COI : AFFIMED provided research support for this study .